Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · operational-macro

Elevar Therapeutics Receives FDA Conditional Acceptance of LYRFIGTU as Brand Name ...

22 September 2026 · By · Wire by Fusion42

Published

22 September 2026

Topic

operational-macro

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at biospace.com →

◆ Verified

Fusion42 · 22 September 2026 · Fusion42 review

Elevar Therapeutics received conditional FDA acceptance for LYRFIGTU as the brand name for lirafugratinib, a drug under Priority Review for treating advanced cholangiocarcinoma with FGFR2 fusion or rearrangement; final name approval awaits drug approval expected by September 25, 2026.

This Wire brief sits within Fusion42's coverage of Biotech, and 3 sources have reported it between 22 Sep 2026 and 25 Sep 2026.

◆ ◆ The Wire takeaway

You face a near-term FDA decision that can open a new cancer drug market for FGFR2-targeted therapies. Prepare for rapid launch activities to access patients newly eligible for treatment.

◆ Coverage

3 sources · first reported 22 Sep 2026 · latest 25 Sep 2026

◆ Related on Wire

◆ Topics

BiotechFDA-approvaloncologycholangiocarcinomalirafugratinibclinical-trial